Home › Metabolic Disorders › Tennessee › Nashville
Metabolic Disorders clinical trials in Nashville, TN
4 studies for Metabolic Disorders are looking for participants at sites in and around Nashville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
RecruitingPhase 3
- 89bio Clinical Study Site, Nashville
- 89bio Clinical Study Site, Hermitage · 9 mi away
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
RecruitingPhase 3
- 89bio Clinical Study Site, Nashville
- 89bio Clinical Study Site, Hermitage · 9 mi away
A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
RecruitingPhase 1/2
- Vanderbilt University Medical Center, Nashville
Rare and Atypical Diabetes Network
RecruitingObservational study
- Vanderbilt University, Nashville
About Metabolic Disorders
Your metabolism makes energy from the food you eat. A metabolic disorder disrupts this process. One example is diabetes. Learn more.
More about Metabolic Disorders on MedlinePlus
Metabolic Disorders trials in other cities
- Washington, DC11 studies
- Ann Arbor, MI8 studies
- St. Louis, MO7 studies
- Durham, NC7 studies
- New York City, NY7 studies
- Baltimore, MD6 studies
- Chicago, IL6 studies
- Houston, TX6 studies
- Boston, MA5 studies
- Philadelphia, PA4 studies
- Miami, FL4 studies
- Los Angeles, CA4 studies
Other studies in Nashville
- Non-Small Cell Lung Cancer97 studies
- Breast Cancer81 studies
- Metastatic Cancer70 studies
- Colorectal Cancer69 studies
- Cancer (all types)65 studies
- Ovarian Cancer49 studies
- Prostate Cancer43 studies
- Lung Cancer40 studies
- Head and Neck Squamous Cell Carcinoma39 studies
- Pancreatic Cancer39 studies
- Endometrial Cancer38 studies
- Melanoma33 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.